Piperacillin SodiumCAS# 59703-84-3 |
- GSK256066 2,2,2-trifluoroacetic acid
Catalog No.:BCC1605
CAS No.:1415560-64-3
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Oglemilast
Catalog No.:BCC1817
CAS No.:778576-62-8
- AN-2728
Catalog No.:BCC1361
CAS No.:906673-24-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 59703-84-3 | SDF | Download SDF |
| PubChem ID | 23685000 | Appearance | Powder |
| Formula | C23H26N5NaO7S | M.Wt | 539.54 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Sodium piperacillin | ||
| Solubility | DMSO : 100 mg/mL (185.34 mM; Need ultrasonic) H2O : ≥ 100 mg/mL (185.34 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | sodium;(2S,5R,6R)-6-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | ||
| SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+] | ||
| Standard InChIKey | WCMIIGXFCMNQDS-QMJSIVKPSA-M | ||
| Standard InChI | InChI=1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14+,15-,20+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Piperacillin sodium is a semisynthetic broad-spectrum penicillin for parenteral use derived from D(-)-α-aminobenzylpenicillin. Target: Antibacterial Piperacillin is anantibiotic. It is an extended-spectrum beta-lactam of the ureidopenicillin class.The chemical structure of Piperacillin and other ureidopenicillins incorporates a polar side chain that enhances penetration into Gram-(-) bacteria and reduces susceptibility to cleavage by Gram-(-) beta lactamase enzymes. These properties confer activity against the important hospital pathogen Pseudomonas aeruginosa. Thus Piperacillin is sometimes referred to as an anti-pseudomonal penicillin.When used alone, Piperacillin lacks strong activity against the Gram-(+) pathogenStaphylococcus aureus, as it Piperacillin is broken down by the Gram-(+) beta lactamases. | |||||
Piperacillin Sodium Dilution Calculator
Piperacillin Sodium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8534 mL | 9.2672 mL | 18.5343 mL | 37.0686 mL | 46.3358 mL |
| 5 mM | 0.3707 mL | 1.8534 mL | 3.7069 mL | 7.4137 mL | 9.2672 mL |
| 10 mM | 0.1853 mL | 0.9267 mL | 1.8534 mL | 3.7069 mL | 4.6336 mL |
| 50 mM | 0.0371 mL | 0.1853 mL | 0.3707 mL | 0.7414 mL | 0.9267 mL |
| 100 mM | 0.0185 mL | 0.0927 mL | 0.1853 mL | 0.3707 mL | 0.4634 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections.
- Cephalexin hydrochloride
Catalog No.:BCC4095
CAS No.:59695-59-9
- 6alpha-Hydroxyhispanone
Catalog No.:BCN7416
CAS No.:596814-48-1
- 3-O-Acetyl-beta-boswellic acid
Catalog No.:BCN2672
CAS No.:5968-70-7
- Calyciphylline A
Catalog No.:BCN4098
CAS No.:596799-30-3
- AC 55649
Catalog No.:BCC7359
CAS No.:59662-49-6
- Alpha-Obscurine
Catalog No.:BCN6701
CAS No.:596-55-4
- Glycopyrrolate
Catalog No.:BCC4275
CAS No.:596-51-0
- H-D-Gln-OH
Catalog No.:BCC2920
CAS No.:5959-95-5
- 3-Amino-2-naphthoic acid
Catalog No.:BCC8607
CAS No.:5959-52-4
- Carnosol
Catalog No.:BCN1055
CAS No.:5957-80-2
- H-D-Ala-OtBu.HCl
Catalog No.:BCC2849
CAS No.:59531-86-1
- Boc-Ser-OBzl
Catalog No.:BCC3440
CAS No.:59524-02-6
- Camostat Mesilate
Catalog No.:BCC4894
CAS No.:59721-29-8
- Citalopram hydrobromide
Catalog No.:BCC7063
CAS No.:59729-32-7
- beta-Amyrin palmitate
Catalog No.:BCN4099
CAS No.:5973-06-8
- 1beta,10beta-Epoxy-6beta-isobutyryloxy-9-oxofuranoeremophilane
Catalog No.:BCN7601
CAS No.:59742-11-9
- Cudraflavanone B
Catalog No.:BCN3446
CAS No.:597542-74-0
- Boc-Asp(OMe)-OH.DCHA
Catalog No.:BCC3367
CAS No.:59768-74-0
- 6beta-Angeloyloxy-1beta,10beta-epoxy-9-oxofuranoeremophilane
Catalog No.:BCN7600
CAS No.:59780-08-4
- Cyclosporin C
Catalog No.:BCC8160
CAS No.:59787-61-0
- Vindolinine
Catalog No.:BCN7822
CAS No.:5980-02-9
- UK 14,304
Catalog No.:BCC5226
CAS No.:59803-98-4
- Tenoxicam
Catalog No.:BCC4733
CAS No.:59804-37-4
- Ajmalimine
Catalog No.:BCN3420
CAS No.:59846-31-0
Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium.[Pubmed:10932462]
J Am Pharm Assoc (Wash). 2000 Jul-Aug;40(4):520-4.
OBJECTIVE: To evaluate the physical compatibility and chemical stability of linezolid (Zyvox-Pharmacia) 200 mg/100 mL admixed with aztreonam (Azactam-Squibb) 2 grams and separately with Piperacillin Sodium (Pipracil-Lederle) 3 grams over 7 days at 4 degrees C and 23 degrees C. DESIGN: Controlled experimental trial. SETTING: Laboratory. INTERVENTIONS: Test samples were prepared by adding the required amount of aztreonam or Piperacillin Sodium to separate bags of linezolid injection 200 mg/100 mL. MAIN OUTCOME MEASURES: Physical compatibility and chemical stability based on drug concentrations initially and after 1, 3, 5, and 7 days of storage at 4 degrees C and 23 degrees C. RESULTS: All of the linezolid admixtures with aztreonam and with Piperacillin Sodium were clear when viewed in normal fluorescent room light and with a Tyndall beam. Measured turbidity and particulate content were low and exhibited little change throughout the study at both storage temperatures. High-performance liquid chromatography analysis found little or no loss of linezolid in any sample stored at either temperature throughout the study. Aztreonam in the linezolid admixtures was stable for 7 days, exhibiting less than 5% loss at 4 degrees C and 9% loss at 23 degrees C. Piperacillin Sodium in the linezolid admixtures was stable for 7 days at 4 degrees C, exhibiting no loss, but was stable for only 3 days at 23 degrees C with losses of about 5%. Losses had increased to 9% to 12% after 5 days of storage at room temperature. CONCLUSION: Admixtures of linezolid 200 mg/100 mL with aztreonam 2 grams or Piperacillin Sodium 3 grams were physically compatible and chemically stable for at least 7 days stored at 4 degrees C and for 7 days or 3 days, respectively, at 23 degrees C.
Stability of piperacillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.[Pubmed:23981892]
Int J Pharm Compd. 2001 May-Jun;5(3):230-1.
A stability-indicating high-performance liquid chromatography (HPLC) assay method was used to study the stability of Piperacillin Sodium (40 mg/mL) in 0.9% sodium chloride injection at 25 deg C and 5 deg C in polypropylene syringes. The concentrations of the drug were directly related to peak heights, and the percent relative standard deviation (RSD) based on five injections was 0.8. Three products of decomposition separated from the intact drug. At 25 deg C, the loss in potency was less than 10% after 5 days of storage, and at 5 deg C, it was less than 2% when stored for 28 days. The pH value of the injection decreassed from 5.3 to 4.4 when stored for 28 days at 5 deg C. The drug was not adsorbed onto the syringes, and the physical appearance of the injection did not change.
[The clinical evaluation of piperacillin and sulbactam sodium in treatment of respiratory, urinary tracts and other infections in 579 patients].[Pubmed:22041274]
Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):601-3.
OBJECTIVE: To evaluate the clinical efficacy and safety of piperacillin and sulbactam sodium combinations in the treatment of common infections. METHODS: This was a multi-centre, prospective and open study. All subjects from 57 wards caught common infection like respiratory (RTI) or urinary diseases (UTI). The dosages of piperacillin and sulbactam sodium combinations 2.5 g injection were determined according to indications: for adult, 2.5 g or 5 g per time, 2 time/day; for severe or obstinate infection, 2.5 g or 5 g per time, 3 time/day. General information, clinical response pre- and post-treatment, infected locus, drug recipe and protocol, prognosis and adverse reaction were recorded. RESULTS: Data of 579 cases were collected with 388 males and 191 females. The average age was (66.8 +/- 17.0) years. There were 500 patients who were suffering with RTI, with 362 cases of pneumonia, 102 of acute exacerbation of chronic bronchitis, and 36 of other infections. There were 50 cases with UTI, with 31 of simple urinary tract infection, and 19 of complex urinary tract infection. In addition, there were 9 cases of combined RTI and UTI, and 20 of other infections including peritonitis. The average duration of anti-microbial for RTI and UTI was (8.65 +/- 3.78) days and (7.45 +/- 3.46) days respectively with the total efficacy rate was 92.6% and 98.0% respectively for RTI and UTI. The incidence of adverse events was only 0.86% (5 cases), including nausea, rash, itching, ALT elevation and suspected drug induced fever in each one. CONCLUSION: Piperacillin and sulbactam sodium compound had high clinical efficacy and safety in the treatment of common infections including RTI and UTI.
Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions.[Pubmed:23784164]
Am J Health Syst Pharm. 2013 Jul 1;70(13):1163-6.
PURPOSE: The physical compatibility of vancomycin and Piperacillin Sodium-tazobactam at dosing concentrations commonly administered during prolonged infusions was studied. METHODS: Concentrations of vancomycin and Piperacillin Sodium-tazobactam typically used in prolonged infusions were evaluated. Vancomycin hydrochloride and Piperacillin Sodium-tazobactam were reconstituted with 0.9% sodium chloride injection and diluted to the following concentrations: vancomycin, 4 mg/mL; Piperacillin Sodium 30 mg/mL plus tazobactam 3.75 mg/mL; and Piperacillin Sodium 40 mg/mL plus tazobactam 5 mg/mL. Combinations of vancomycin and Piperacillin Sodium-tazobactam were tested using simulated Y-site administration; phenytoin served as a positive control for precipitation with vancomycin. Each combination was prepared in triplicate, alternating the order of drug addition, and stored without light protection at room temperature. The resultant admixtures were microscopically observed and subjected to particle-size and turbidity analyses for five days. Statistical analyses were performed using two-way repeated measures analysis of variance with conservative Bonferroni corrections for multiple comparisons. RESULTS: Vancomycin was compatible with Piperacillin Sodium-tazobactam in the concentrations tested. No particulate matter was observed by the unaided eye. Similarly, the antibiotic admixtures displayed no differences microscopically, by particle-size analysis, or by turbidity analysis when compared with negative controls at five days. CONCLUSION: Vancomycin 4 mg/mL and Piperacillin Sodium 30 mg/mL plus tazobactam 3.75 mg/mL or Piperacillin Sodium 40 mg/mL plus tazobactam 5 mg/mL were physically compatible during simulated Y-site injection at room temperature without light protection for five days.
